Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008

Authors

Thomas J. Moore, George Washington UniversityFollow
Curt D. Furberg, Wake Forest University

Document Type

Response or Comment

Publication Date

1-2014

Journal

JAMA Internal Medicine

Volume

Volume 174, Issue 1

Inclusive Pages

90-95

Keywords

Clinical Trials as Topic--statistics & numerical data; Drug Approval--statistics & numerical data; Product Surveillance, Postmarketing--statistics & numerical data

Comments

Comment in:

Can expedited FDA drug approval without expedited follow-up be trusted? [JAMA Intern Med. 2014]

APA Citation

Moore, T.J., Furberg, C.D. (2014). Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: The class of 2008. JAMA Internal Medicine, 174(1), 90-95.

Peer Reviewed

1